#METABOLOMICS WORKBENCH lgmartins1984_20220331_114038 DATATRACK_ID:3151 STUDY_ID:ST002133 ANALYSIS_ID:AN003488 PROJECT_ID:PR001351
VERSION             	1
CREATED_ON             	March 31, 2022, 3:40 pm
#PROJECT
PR:PROJECT_TITLE                 	Untarget metabolomics of HIV patients carrier
PR:PROJECT_TYPE                  	NMR-based metabolomics
PR:PROJECT_SUMMARY               	Analysis of metabolite variation in HIV patients carrier blood serum in response
PR:PROJECT_SUMMARY               	to treatment with effervencent glutamine.
PR:INSTITUTE                     	University of Campinas
PR:DEPARTMENT                    	Organic Chemistry
PR:LABORATORY                    	Biological Chemistry Lab
PR:LAST_NAME                     	Martins
PR:FIRST_NAME                    	Lucas
PR:ADDRESS                       	Cidade Universitário Zeferino Vaz, Campinas, SP, Brazil
PR:EMAIL                         	lgmartins1984@gmail.com
PR:PHONE                         	+5519992947044
PR:FUNDING_SOURCE                	FAPESP, INCT-Bio
#STUDY
ST:STUDY_TITLE                   	Metabolite variation in the blood serum of HIV patients carrier treated with
ST:STUDY_TITLE                   	effervecent glutamine
ST:STUDY_TYPE                    	Liquid NMR experiments
ST:STUDY_SUMMARY                 	It was demonstrated that effervescent glutamine supplementation in people living
ST:STUDY_SUMMARY                 	with HIV/AIDS increased the amount of CD4+ T lymphocytes. , decreased the serum
ST:STUDY_SUMMARY                 	levels of biomarkers of inflammation, and introduced health benefits. Herein,
ST:STUDY_SUMMARY                 	NMR spectroscopy was applied to evaluate if oral ingestion of glutamine (12.5 g)
ST:STUDY_SUMMARY                 	for 30 days can be measured through serum metabolite variations and if the
ST:STUDY_SUMMARY                 	reported benefits might correlate to small metabolites' changes in a chosen
ST:STUDY_SUMMARY                 	cohort of individuals. The HIV/AIDS group has been carefully selected and
ST:STUDY_SUMMARY                 	studied before and after the 30-days of supplementation with the glutamine,
ST:STUDY_SUMMARY                 	together with the matched non-HIV carrier patients' group. The group of HIV/AIDS
ST:STUDY_SUMMARY                 	individuals presented lower (p < 0.05) levels of choline, creatine, pyruvate,
ST:STUDY_SUMMARY                 	glutamate, lysine, and tyrosine when compared to the non-HIV carrier patients.
ST:STUDY_SUMMARY                 	On the other hand, serum concentrations of glucose, lipids, lactate, glutamine,
ST:STUDY_SUMMARY                 	phenylalanine, and threonine were higher (p < 0.05) in HIV/AIDS individuals. The
ST:STUDY_SUMMARY                 	variation in metabolites as a result of treatment with glutamine is consistent
ST:STUDY_SUMMARY                 	with the improvements observed in these patients and may lead us to suggest the
ST:STUDY_SUMMARY                 	introduction of the effervescent glutamine supplementation to antiretroviral
ST:STUDY_SUMMARY                 	therapies in people living with HIV/AIDS.
ST:INSTITUTE                     	University of Campinas
ST:DEPARTMENT                    	Organic Chemistry
ST:LABORATORY                    	Biological Chemistry Lab
ST:LAST_NAME                     	MARTINS
ST:FIRST_NAME                    	LUCAS
ST:ADDRESS                       	Rua Josué de Castro, s/n - Cidade Universitária, Campinas - SP, 13083-970
ST:EMAIL                         	lgmartins1984@gmail.com
ST:PHONE                         	+5519992947044
ST:NUM_GROUPS                    	3
ST:TOTAL_SUBJECTS                	24
ST:NUM_MALES                     	10
ST:NUM_FEMALES                   	14
ST:STUDY_COMMENTS                	Crossover study
#SUBJECT
SU:SUBJECT_TYPE                  	Human
SU:SUBJECT_SPECIES               	Homo sapiens
SU:TAXONOMY_ID                   	9606
SU:AGE_OR_AGE_RANGE              	40.3 ± 3.9
SU:HUMAN_NUTRITION               	Effervecent glutamine administration (12.5g, once a day for 30 days)
SU:HUMAN_INCLUSION_CRITERIA      	Patients living with HIV from Public Service Health Care for Sexually
SU:HUMAN_INCLUSION_CRITERIA      	Transmitted Diseases/AIDS Center of Maringá City, Paraná, Brazil, with same
SU:HUMAN_INCLUSION_CRITERIA      	ART treatment for at least 1 year.
SU:HUMAN_EXCLUSION_CRITERIA      	Patients which were transferred, who abandoned treatment, and those who had not
SU:HUMAN_EXCLUSION_CRITERIA      	been evaluated for viral load and CD4+ T lymphocyte counts were excluded.
#FACTORS
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data
SUBJECT_SAMPLE_FACTORS           	-	1pre1	Sample class:BT	RAW_FILE_NAME=1pre1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	2pre1	Sample class:BT	RAW_FILE_NAME=2pre1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	4pre1	Sample class:BT	RAW_FILE_NAME=4pre1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	6pre1	Sample class:BT	RAW_FILE_NAME=6pre1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	8pre1	Sample class:BT	RAW_FILE_NAME=8pre1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	9pre1	Sample class:BT	RAW_FILE_NAME=9pre1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	10pre1	Sample class:BT	RAW_FILE_NAME=10pre1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	12pre1	Sample class:BT	RAW_FILE_NAME=12pre1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	13pre1	Sample class:BT	RAW_FILE_NAME=13pre1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	16pre1	Sample class:BT	RAW_FILE_NAME=16pre1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	14pre1	Sample class:BT	RAW_FILE_NAME=14pre1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	17pre1	Sample class:BT	RAW_FILE_NAME=17pre1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	2pre2	Sample class:BT	RAW_FILE_NAME=2pre2; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	4pre2	Sample class:BT	RAW_FILE_NAME=4pre2; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	6pre2	Sample class:BT	RAW_FILE_NAME=6pre2; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	8pre2	Sample class:BT	RAW_FILE_NAME=8pre2; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	9pre2	Sample class:BT	RAW_FILE_NAME=9pre2; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	10pre2	Sample class:BT	RAW_FILE_NAME=10pre2; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	12pre2	Sample class:BT	RAW_FILE_NAME=12pre2; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	13pre2	Sample class:BT	RAW_FILE_NAME=13pre2; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	14pre2	Sample class:BT	RAW_FILE_NAME=14pre2; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	15pre2	Sample class:BT	RAW_FILE_NAME=15pre2; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	16pre2	Sample class:BT	RAW_FILE_NAME=16pre2; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	17pre2	Sample class:BT	RAW_FILE_NAME=17pre2; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	1pos1	Sample class:AT	RAW_FILE_NAME=1pos1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	2pos1	Sample class:AT	RAW_FILE_NAME=2pos1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	4pos1	Sample class:AT	RAW_FILE_NAME=4pos1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	6pos1	Sample class:AT	RAW_FILE_NAME=6pos1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	8pos1	Sample class:AT	RAW_FILE_NAME=8pos1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	9pos1	Sample class:AT	RAW_FILE_NAME=9pos1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	10pos1	Sample class:AT	RAW_FILE_NAME=10pos1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	12pos1	Sample class:AT	RAW_FILE_NAME=12pos1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	13pos1	Sample class:AT	RAW_FILE_NAME=13pos1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	14pos1	Sample class:AT	RAW_FILE_NAME=14pos1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	15pos1	Sample class:AT	RAW_FILE_NAME=15pos1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	17pos1	Sample class:AT	RAW_FILE_NAME=17pos1; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	1pos2	Sample class:AT	RAW_FILE_NAME=1pos2; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	4pos2	Sample class:AT	RAW_FILE_NAME=4pos2; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	6pos2	Sample class:AT	RAW_FILE_NAME=6pos2; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	8pos2	Sample class:AT	RAW_FILE_NAME=8pos2; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	10pos2	Sample class:AT	RAW_FILE_NAME=10pos2; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	12pos2	Sample class:AT	RAW_FILE_NAME=12pos2; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	13pos2	Sample class:AT	RAW_FILE_NAME=13pos2; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	14pos2	Sample class:AT	RAW_FILE_NAME=14pos2; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	15pos2	Sample class:AT	RAW_FILE_NAME=15pos2; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	16pos2	Sample class:AT	RAW_FILE_NAME=16pos2; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
SUBJECT_SAMPLE_FACTORS           	-	17pos2	Sample class:AT	RAW_FILE_NAME=17pos2; NMR sample ID=3; Sample description=Blood serum; NMR experiment=1H CPMG
#COLLECTION
CO:COLLECTION_SUMMARY            	Serum samples were obtained from 12 HIV/AIDS patients before (day 0) and after
CO:COLLECTION_SUMMARY            	glutamine (day 31) administration, and from healthy donors.
CO:SAMPLE_TYPE                   	Blood (serum)
CO:STORAGE_CONDITIONS            	-80℃
#TREATMENT
TR:TREATMENT_SUMMARY             	Glutamine supplementation (12.5g/day for 30 days)
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	Serum samples were carefully separated and aliquoted in duplicates (250 μL each
SP:SAMPLEPREP_SUMMARY            	one) into cryovials and stored at -80 °C. Samples (250 μL) were thawed on ice,
SP:SAMPLEPREP_SUMMARY            	mixed with 250 μL of deuterium oxide (D2O 99.9%, Cambridge Isotope
SP:SAMPLEPREP_SUMMARY            	Laboratories, Inc., Andover, USA) at room temperature, centrifuged at 12,000 ×
SP:SAMPLEPREP_SUMMARY            	g for 2 min at 4 °C, and transferred into 5 mm NMR tubes
SP:PROCESSING_STORAGE_CONDITIONS 	-80℃
#ANALYSIS
AN:ANALYSIS_TYPE                 	NMR
#NMR
NM:INSTRUMENT_NAME               	Avance 600 Bruker
NM:INSTRUMENT_TYPE               	FT-NMR
NM:NMR_EXPERIMENT_TYPE           	1D-1H
NM:SPECTROMETER_FREQUENCY        	600 MHz for 1H
NM:NMR_PROBE                     	inverse triple-core probe (TBI)
NM:NMR_SOLVENT                   	H2O/D2O
NM:NMR_TUBE_SIZE                 	5 mm
NM:NMR_RESULTS_FILE               	ST002133_AN003488_Results.txt	UNITS:intensity
#END